TELA Bio, Inc. (TELA): who owns it and who trades it
As of Nov 16, 2026, TELA insiders reported 7 purchases worth $4.2M in the last 12 months. The largest buyer was EW Healthcare Partners Fund 2-UGP, LLC (10% owner), with $4M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling TELA Bio
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TELA
44 funds and institutions reported TELA shares worth $23.7M at the end of Q2 2026, about 71% of the company. The largest holder is Nantahala Capital Management, LLC with 26.3%.
Funds and institutions (13F) 71%Everyone else 29%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11.79M | 26.35% | $8.8M | +129% |
| Essex Woodlands Management, Inc. | 7.71M | 17.24% | $5.8M | No change |
| Stonepine Capital Management, LLC | 2.66M | 5.95% | $2M | +2% |
| Silverarc Capital Management, LLC | 2.14M | 4.78% | $1.6M | -5% |
| Vanguard Capital Management LLC | 1.57M | 3.51% | $1.2M | +2% |
| DAFNA Capital Management LLC | 1.44M | 3.22% | $1.1M | No change |
| Perkins Capital Management Inc | 1.38M | 3.07% | $1M | -3% |
| Sio Capital Management, LLC | 636,300 | 1.42% | $477K | No change |
| WealthTrust Axiom LLC | 457,734 | 1.02% | $343K | +21% |
| Geode Capital Management, LLC | 389,223 | 0.87% | $292K | -14% |
| BlackRock, Inc. | 374,516 | 0.84% | $281K | -20% |
| Vanguard Fiduciary Trust Co | 213,138 | 0.48% | $160K | +1% |
| Up Strategic Wealth Investment Advisors LLC | 99,888 | 0.22% | $91.4K | No change |
| Embree Financial Group | 90,906 | 0.20% | $68.2K | -23% |
| Northern Trust Corp | 74,790 | 0.17% | $56.1K | -57% |
| Raymond James Financial Inc | 67,700 | 0.15% | $50.8K | +36% |
| State Street Corp | 63,383 | 0.14% | $47.5K | No change |
| Renaissance Technologies LLC | 58,100 | 0.13% | $43.6K | +10% |
| PNC Financial Services Group, Inc. | 53,612 | 0.12% | $40.2K | No change |
| Destiny Wealth Partners, LLC | 52,500 | 0.12% | $38.3K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TELA insiders reported $4.2M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Joseph H Capper | Director | Purchase | 25,000 | $1.22 | $30.5K | Form 4 |
| Sep 16, 2026 | Joseph H Capper | Director | Purchase | 50,000 | $1.17 | $58.5K | Form 4 |
| Sep 15, 2026 | Joseph H Capper | Director | Purchase | 50,000 | $1.06 | $53K | Form 4 |
| Sep 14, 2026 | Joseph H Capper | Director | Purchase | 25,000 | $1.02 | $25.5K | Form 4 |
| Aug 17, 2026 | Heather C Getz | CEO | Purchase | 12,500 | $0.66 | $8.2K | Form 4 |
| Aug 14, 2026 | Heather C Getz | CEO | Purchase | 15,000 | $0.70 | $10.5K | Form 4 |
| Nov 17, 2025 | EW Healthcare Partners Fund 2-UGP, LLC +3 | 10% owner | Purchase | 3.60M | $1.11 | $4M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| EW Healthcare Partners Fund 2-UGP, LLC | 10% owner | $4M | – | Nov 17, 2025 |
| Joseph H Capper | Director | $168K | – | Sep 17, 2026 |
| Heather C Getz | Chief Executive Officer, Director | $18.8K | – | Aug 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TELA short interest
Low short interest. 1.3% of TELA shares are sold short: about 1 share in 77. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 579,565 TELA shares were sold short, 1.3% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 114,217 shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 579,565 | 1.29% | -9% | 114,217 | 5.1 |
| Oct 15, 2026 | 638,950 | 1.42% | +36% | 166,514 | 3.8 |
| Sep 30, 2026 | 469,145 | 1.04% | -15% | 261,819 | 1.8 |
| Sep 15, 2026 | 550,824 | 1.23% | +43% | 247,772 | 2.2 |
| Aug 31, 2026 | 384,643 | 0.86% | +14% | 348,892 | 1.1 |
| Aug 14, 2026 | 338,486 | 0.75% | -1% | 239,148 | 1.4 |
| Jul 31, 2026 | 341,493 | 0.76% | -6% | 32,549 | 10.5 |
| Jul 15, 2026 | 361,787 | 0.81% | -22% | 72,956 | 5.0 |
| Jun 30, 2026 | 466,218 | 1.04% | +54% | 118,449 | 3.9 |
| Jun 15, 2026 | 302,880 | 0.68% | -60% | 114,154 | 2.6 |
| May 29, 2026 | 748,090 | 1.67% | -5% | 102,619 | 7.3 |
| May 15, 2026 | 787,044 | 1.76% | +3% | 314,738 | 2.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
TELA Bio company events
TELA Bio filed 15 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Oct 8, 2026VoteReported shareholder vote results. Filing
- Oct 6, 2026AnnouncementTELA Bio, Inc. received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) and the matter is now closed. Filing
- Oct 5, 2026AnnouncementTELA Bio, Inc. issued a press release announcing that it has received U.S. Food and Drug Administration 510(k) clearance for its Liora Monofilament Scaffold product. Filing
- Sep 29, 2026AgreementTELA Bio, Inc. entered into a Limited Consent to Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent, and the lenders party thereto constituting the Required Lenders under the Credit Agreement (as defined below). Filing
- Sep 18, 2026ListingAs previously disclosed, on March 17, 2026, TELA Bio, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on The… Filing
- Aug 31, 2026LeadershipEffective on August 31, 2026, Roberto Cuca stepped down from his position as the Company’s Chief Financial Officer, Chief Operating Officer, Corporate Secretary and principal financial officer. Filing
- Aug 13, 2026LeadershipAmended an earlier report. Of the Current Report on Form 8-K filed on August 4, 2026 to disclose information regarding material modifications to a material compensatory plan, contract or arrangement as to which a named executive officer of the registrant participates that were effected pursuant to an agreement entered into… Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Aug 4, 2026LeadershipThe Board of Directors of TELA Bio, Inc. determined that, Antony Koblish will no longer serve as the Company’s Chief Executive Officer and the principal executive officer, effective on August 3, 2026. Filing
- Jun 11, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of TELA Bio, Inc., the Company’s stockholders approved the amendment to the Company’s Amended and Restated 2019 Equity Incentive Plan, as amended, to, among other things, increase the authorized shares issuable under the A&R 2019 Plan by 3,500,000 shares. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 30, 2026LeadershipDoug Evans, Chairman of the Board of Directors of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders and will retire from the Board, including the Compensation Committee of the Board and Audit Committee of the… Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Mar 20, 2026ListingTELA Bio, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
TELA Bio financials
Famous investors that hold TELA
1 of the 50 well-known investors we track reported holding TELA in their latest 13F filing. The largest position is Ken Griffin's, worth $120K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 104,467 | $120K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TELA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Stonepine Capital Management, LLC | 13G/A | 0.0% |
| Nov 16, 2026 | Stonepine Capital Management, LLC | 13G/A | 0.0% |
| Nov 13, 2026 | North Run Capital, LP | 13G/A | 7.8% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 14.5% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 14.5% |
| Nov 13, 2026 | North Run Capital, LP | 13G/A | 7.8% |
Questions about TELA Bio, Inc. (TELA) stock
Who owns the most TELA stock?
The largest reported owner of TELA Bio, Inc. (TELA) is Nantahala Capital Management, LLC, with 26.3% of the company. In total, 44 funds and institutions reported holding TELA at the end of Q2 2026, together about 71% of the shares. See the largest owners.
Are TELA insiders buying or selling?
In the last 12 months, TELA insiders reported 7 open-market purchases worth $4.2M and no sales. The latest trade was on Sep 17, 2026. See every trade.
What is the short interest in TELA?
As of Oct 30, 2026, 579,565 TELA shares were sold short, 1.3% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 114,217 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold TELA?
1 of the 50 well-known investors we track reported TELA in their latest 13F filing, including Ken Griffin. The largest position is worth $120K. See all holders.
Executive pay
TELA Bio's chief executive was paid a total of $2M for the year ended Dec 31, 2025, down 6% from $2.1M the year before. In the last 12 months, TELA Bio's executives and directors bought $186K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.